43 results on '"Trzaskoma A"'
Search Results
2. Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis
3. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
4. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma
5. Characteristics of patients with chronic spontaneous urticaria who are late-responders to omalizumab
6. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis
7. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
8. Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life
9. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies
10. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria
11. Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy
12. Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma
13. Corrigendum to ‘Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis’ [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077]
14. POST HOC ANALYSIS OF CLINICAL CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) BY PULMONARY VASCULAR PHENOTYPE FROM CAPACITY
15. Severity of Asthma Score Predicts Clinical Outcomes in Patients With Moderate to Severe Persistent Asthma
16. IMPACT OF BASELINE CHARACTERISTICS ON LONG-TERM RESPONSE FOLLOWING OMALIZUMAB TREATMENT IN PATIENTS WITH ALLERGIC ASTHMA
17. TIME TO SLEEP IMPROVEMENT IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA TREATED WITH OMALIZUMAB
18. IMPACT OF BASELINE ANGIOEDEMA AND IGE ON RESPONSE TO OMALIZUMAB IN CHRONIC SPONTANEOUS URTICARIA
19. Improvements In The Respiratory-Related Patient-Reported Outcomes AQLQ and miniRQLQ Are Similar Across Different Omalizumab Dosing Regimens
20. IMPROVEMENTS IN SELECT PATIENT-REPORTED OUTCOMES ARE SIMILAR ACROSS DIFFERENT OMALIZUMAB DOSING REGIMENS
21. EFFECT OF SEX ON RESPONSE TO OMALIZUMAB IN PATIENTS WITH ASTHMA
22. TIME TO CLINICALLY MEANINGFUL RESPONSE TO OMALIZUMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA
23. PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA MAY BENEFIT FROM LONGER TREATMENT OR UPDOSING WITH OMALIZUMAB
24. EFFICACY OF PIRFENIDONE ON DYSPNEA IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): RESULTS FROM A POST HOC RESPONDER ANALYSIS
25. REDUCTIONS IN EXACERBATIONS AND HOSPITALIZATIONS ARE SIMILAR ACROSS DIFFERENT OMALIZUMAB DOSING REGIMENS
26. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria
27. A Phase IV, Multicenter, Open-Label Study of Emicizumab Prophylaxis in Persons with Hemophilia a with or without FVIII Inhibitors Undergoing Minor Surgical Procedures
28. Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria
29. Baseline Blood Eosinophils and Reduction of Asthma Exacerbations By Omalizumab in Children with Moderate-to-Severe Allergic Asthma
30. Clinically Significant Improvements in Asthma Patient-Reported Outcomes: Results from the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study
31. Decreased Asthma Exacerbations and Hospitalizations in PROSPERO (Prospective Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab)
32. O020 Asthma exacerbations and lung function decline in children during a 52-week controlled trial of omalizumab
33. P147 Omalizumab reduces healthcare resource use in children
34. P144 Exacerbation-free asthma in children treated with omalizumab
35. Exploratory Analysis of the Roles of Multiple Biomarkers in Predicting Response to Omalizumab in Allergic Asthma
36. Poor Asthma Control Is Associated with Overall Daily Activity Impairment: 3-Year Data from the EXCELS Study of Omalizumab
37. Blood Eosinophils and Serum IgE Predict Response to Omalizumab in Patients with Severe Allergic Asthma: Innovate Trial Post-Hoc Analysis
38. Biomarkers Associated with Response in Patients Initiating Omalizumab: Baseline Levels Among Patients in the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study
39. Response Patterns in Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Patients Treated with Omalizumab for 24 Weeks in Two Randomized, Double-Blind, Placebo-Controlled Clinical Trials (ASTERIA I and GLACIAL)
40. Estimated Asthma Exacerbation Reduction from Omalizumab in an Severe Eosinophilic Asthma Population
41. Impact of Omalizumab Treatment on Concomitant Asthma Medications in Patients With Moderate-to-Severe Allergic Asthma
42. Severity of Asthma Score Prospectively Predicts Clinical Outcomes
43. Failure to Improve during First Day of Therapy Is Predictive of 28-Day Mortality in Severe Sepsi
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.